image: A benign mosquito flavivirus isolated in the Australian Binjari region was used as a vector to mimic dengue virus particles without the associated risk. Structure of this chimeric virus is native and reaches a level of detail never seen before. Under the magnifying glass, water molecules and two "pocket factors" can be seen nestled in the protein shell of the virus. The same approach may be readily applied to any pathogenic flavivirus of known sequence for structure determination, functional analysis and vaccination. view more
Credit: (C) Associate Professor Fasseli Coulibaly
In a recent study, Australian scientists used an original approach to resolve the 3D structure of flaviviruses with an unprecedented level of detail, identifying small molecules known as 'pocket factors' as new therapeutic targets.
Flaviviruses infect humans by mosquito or tick bite, with symptoms ranging from fever and myalgia to life-threatening neurological and congenital conditions. Flaviviruses such as dengue, yellow fever and Zika threaten almost a third of the world's population, and new flaviviruses emerge regularly from animal reservoirs with the potential to cause epidemics.
There are currently no approved antiviral drugs for flavivirus infection and most flaviviruses lack a vaccine. Structures of infectious particles are essential to map the vulnerabilities in the viral outer surface to design better therapeutics. However, structure determination of highly pathogenic flaviviruses is only possible in very few locations across the world where microscopes are contained in high biosecurity environments.
In the study, published in Nature Communications, a team led by Associate Professor Fasséli Coulibaly from Monash University and Associate Professor Daniel Watterson from the University of Queensland, have generated three new flavivirus structures using an approach that does not require the same level of containment.
This approach takes advantage of a unique flavivirus first isolated from mosquitoes in the Binjari area. The virus has no known vertebrate - specifically human - host, making it easy to manipulate without risk of human infection. The researchers used the Binjari virus as a platform to produce benign chimeric viruses with the outer shell of medically-relevant viruses.
The team used the Ramaciotti Centre for Cryo-Electron Microscopy at Monash University to determine structures of the chimeric particles. They found that these viruses mimic the infectious particles of several pathogenic flaviviruses in the finest details. This provides a universal path to the safe and rapid structure determination for existing and emerging flaviviruses.
"Because the structural proteins are derived from the human-infecting virus, the particles look like the pathogenic virus. It means that we can determine the structure of these proteins in a native context and that these particles can be used for vaccinal and diagnostic purposes," said Associate Professor Watterson.
Associate Professor Coulibaly said the level of detail of these models was unprecedented with the ability to visualise water molecules and tiny pocket factors nestled within the infectious particles.
"Due to the impressive resolution of our structures we were able to build accurate models for these viruses. We saw how the pocket factors bind to conserved parts found in all pathogenic flaviviruses. Their location suggests they could be the final linchpin to ensure the infectious particle is securely fastened before its release from the cell," he said.
###
This study builds on the progress made by the research team in understanding flavivirus maturation published recently in Science Advances. Together the studies identify the uptake of pocket factors as a potential target for the design of broad-spectrum therapeutics.
The joint first authors are Dr Joshua Hardy in the Coulibaly lab of the Biomedicine Discovery Institute at Monash University and Dr Natalee Newton in the Watterson lab at the University of Queensland.
Read the full paper in Nature Communications titled: A unified route for flavivirus structures uncovers essential pocket factors conserved across pathogenic viruses. DOI: 10.1038/s41467-021-22773-1
About the Monash Biomedicine Discovery Institute at Monash University
Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Spanning six discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection and Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
For Media Enquiries please contact:
Wendy Smith - Communications Manager Monash University
E: wendy.smith1@monash.edu
T: +61 (0) 425 725 836
For more Monash media stories, visit our news and events site
Journal
Nature Communications